Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI)

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 10, 2011, Pages 2398-2404

  Oermann, Christopher M ^a   Mccoy, Karen S ^b   Retsch bogart, George Z ^c   Gibson, Ronald L ^d   Mckevitt, Matthew ^e   Montgomery, A Bruce ^e  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

^e GILEAD SCIENCES   (United States)

Author keywords

Chronic infection; Cystic fibrosis; Resistance

Indexed keywords

AZTREONAM; AZTREONAM LYSINE; CEFTAZIDIME; CIPROFLOXACIN; MEROPENEM; PIPERACILLIN; TOBRAMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM EXAMINATION; CLINICAL EFFECTIVENESS; CYSTIC FIBROSIS; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PHASE 3 CLINICAL TRIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SPUTUM CULTURE; SPUTUM EXAMINATION; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZTREONAM; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; LUNG; MALE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

EID: 80052892852     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr303     Document Type: Article

References (23)

1. Gibson RL, Burns JL, Ramsey BW. State of the art: pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168: 918-51.
2. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992; 12: 158-61.
3. Li Z, Kosorok MR, Farrell PM et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005; 293: 581-8.
4. Mathee K, Narasimhan G, Valdes C et al. Dynamics of Pseudomonas aeruginosa genome evolution. Proc Natl Acad Sci USA 2008; 105: 3100-5.
5. Ciofu O, Mandsberg LF, Bjarnsholt T et al. Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants. Microbiology (Reading, England) 2010; 156: 1108-19.
6. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry Annual Data Report, 2008. Bethesda: Cystic Fibrosis Foundation, 2009; 66.
7. Flume PA, O'Sullivan BP, Robinson KA et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176: 957-69.
8. Emerson J, McNamara S, Buccat AM et al. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol 2010; 45: 363-70.
9. Retsch-Bogart GZ, Quittner AL, Gibson RL et al. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest 2009; 135: 1223-32.
10. McCoy KS, Quittner AL, Oermann CM et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178: 921-8.
11. Oermann CM, Retsch-Bogart GZ, Quittner AL et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010; 45: 1121-34.
12. Cystic Fibrosis Foundation. Microbiology and Infectious Disease in Cystic Fibrosis. Consensus Conference: Concepts in Care, vol. 5, section 1. Bethesda: Cystic Fibrosis Foundation, 1994.
13. Burns JL, Emerson J, Stapp JR et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998; 27: 158-63.
14. Etherington C, Hall M, Conway S et al. Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis. J Antimicrob Chemother 2008; 61: 425-7.
15. Johnson C, Butler SM, Konstan MW et al. Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest 2003; 123: 20-7.
16. Zgurskaya HI, Nikaido H. Bypassing the periplasm: reconstitution of the AcrAB multidrug efflux pump of Escherichia coli. Proc Natl Acad Sci USA 1999; 96: 7190-5.
17. Aires JR, Kohler T, Nikaido H et al. Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. J Antimicrob Chemother 1999; 43: 2624-8.
18. Masuda N, Sakagawa E, Ohya S et al. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. J Antimicrob Chemother 2000; 44: 3322-7.
19. Maseda H, Yoneyama H, Nakae T. Assignment of the substrate-selective subunits of the MexEF-OprN multidrug efflux pump of Pseudomonas aeruginosa. J Antimicrob Chemother 2000; 44: 658-64.
20. Islam S, Oh H, Jalal S et al. Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Clin Microbiol Infect 2009; 15: 60-6.
21. Cavallo JD, Leblanc F, Fabre R. [Surveillance of Pseudomonas aeruginosa sensitivity to antibiotics in France and distribution of β-lactam resistance mechanisms: 1998 GERPB study]. Pathol Biol (Paris) 2000; 48: 472-7.
22. Juan C, Moya B, Perez JL et al. Stepwise upregulation of the Pseudomonas aeruginosa chromosomal cephalosporinase conferring high-level β-lactam resistance involves three AmpD homologues. J Antimicrob Chemother 2006; 50: 1780-7.
23. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34: 634-40.